New phase 4 data from Vertex Pharmaceuticals revealed that more than 90% of patients recovering from aesthetic or reconstructive surgery remained opioid-free when treated with Journavx (suzetrigine) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results